Immix Biopharma, Inc.

IMMX

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Perceptive Advisors Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$13.3M

1 fund

Feb 17, 2026

$1.8M

1 fund

-87% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Perceptive AdvisorsNEWFeb 17, 2026

Shares: 338,941Value: $1.8M

# Signal Note: Perceptive Advisors Initiates IMMX Position Perceptive Advisors' $1.8M entry into Immix Biopharma signals conviction in the company's lead program, IMX-110 (retinal gene therapy for dry AMD), which is advancing toward Phase 2 initiation in 2024. Edelman's track record backing early-stage biotech with validated mechanisms makes this notable; near-term catalysts include Phase 2 enrollment data and potential additional indication expansion in inherited retinal diseases.

Eventide Asset ManagementNEWFeb 13, 2026

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

IVVD2 funds DXCM2 funds AMLX2 funds NRIX2 funds AAVXF2 funds ISRG2 funds KYMR2 funds AXSM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Eventide Initiates IMMX Position Eventide's $13.3M entry into Immix Biopharma signals confidence in the company's Phase 2 pipeline for rare/orphan indications, likely driven by upcoming clinical readouts or regulatory clarity on lead candidates. The position size (~2.5M shares) represents meaningful conviction from a values-focused manager, suggesting the biotech's therapeutic approach aligns with ESG-oriented investment theses while offering clinical-stage upside.